The observed down-regulation of FOS in PTC (Figure 2) confirms the findings of some groups [42,43] but contradicts its frequent (however not 100%) up-regulation reported by another group in 40 patients with thyroid cancer and 20 with benign thyroid diseases [44]. The gene discussed is FOS; the disease is thyroid gland carcinoma.